secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009772
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.05, 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyra suspends LYR-210 development, lays off nearly all staff; CEO/CFO become consultants
--------------------------------------------------------------------------------

- Board approved plan to suspend LYR-210 development and reduce workforce affecting substantially all employees, effective Jan 12, 2026.
- CEO Dr. Maria Palasis and CFO Jason Cavalier terminated; they signed consulting agreements with monthly fees of $78,125 and $55,555.50, respectively.
- Cash and equivalents $22.1M as of Sep 30, 2025; expected runway extended to Q3 2026.
- Engaged SSG Capital Advisors to explore strategic alternatives; no assurance of any transaction.
- Positive ENLIGHTEN 2 Phase 3 data for LYR-210 (June 2025) but capital constraints force halt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000119312526009772/0001193125-26-009772-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000119312526009772/d27712d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009772

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer